Biosimulytics.ai: Accelerating Drug Development with AI-Powered Crystal Structure Prediction

Biosimulytics.ai is a cutting-edge predictive technology platform designed for in silico drug development, leveraging physics-based modeling, artificial intelligence, quantum computing, and high-performance computing to enable early-stage identification and de-risking of polymorphic forms from 2D chemical diagrams. As a platform-as-a-service (PaaS), CHEMINA™ offers pharmaceutical and biotech companies, contract research organizations (CROs), and contract development and manufacturing organizations (CDMOs) a powerful tool to reduce R&D uncertainty, accelerate timelines, and improve the success rate of bringing new medicines to market. The platform supports critical stages of drug development, including preclinical and clinical screening, by assessing competing form risks, intellectual property (IP) patent challenges, and manufacturing feasibility. Backed by a multidisciplinary team from University College Dublin and recognized as an award-winning EIC Accelerator recipient among Europe’s top 5% deep tech ventures, Biosimulytics.ai operates on secure, bespoke computing infrastructure in collaboration with Viridien. Its innovative approach combines scientific rigor with advanced computational technologies to deliver reliable, actionable insights in drug formulation.

Key Features:

• Crystal Structure Prediction (CSP) for small molecules
• Early-stage prediction of polymorphic forms from 2D chemical diagrams
• Physics-based modeling integrated with AI and quantum computing
• High-performance computing (HPC) support for complex simulations
• Preclinical screening for competing form risk assessment
• Clinical stage screening for IP patent and manufacturing risks
• Platform-as-a-service (PaaS) delivery via CHEMINA™
• Secure, bespoke computing infrastructure
• Multinational and multidisciplinary expert collaboration
• Integration with pharma, biotech, CROs, CDMOs, and technology partners

Pricing: Biosimulytics.ai offers a subscription-based pricing model tailored for enterprise and research-driven clients, with flexible plans available upon request.

Conclusion: Biosimulytics.ai is a transformative force in pharmaceutical R&D, combining advanced computational technologies with deep scientific expertise to streamline drug development and de-risk formulation challenges from the earliest stages.